Leukemia (2016) 30, 2106-2109; doi:10.1038/leu. 2016.146 Tight regulation of canonical Wnt/β-catenin signaling is critical for maintaining normal hematopoiesis and its deregulation contributes to leukemia development. 1 β-catenin, a central molecule in the canonical Wnt/β-catenin signaling pathway, acts as a nuclear transcriptional co-activator with the lymphoid enhancer factor/T-cell factor (LEF/TCF) family to stimulate transcription of various target genes. 2 The intracellular level of β-catenin is controlled by a degradation complex consisting of Apc, Gsk-3β, Axin 1 and Ck-1. 2 We found that loss of Apc leads to bone marrow failure due to exhaustion of hematopoietic stem and progenitor cells in mice. 3 A marked decrease of Mac-1 + Gr-1 + myeloid cells and rapid depletion of granulocyte-macrophage progenitors (GMPs), but not megakaryocyte-erythrocyte progenitors were observed in both Apc-null 3 and transgenic mice with expression of stabilized β-catenin. 4, 5 However, whether this decrease of myeloid cells is due to a blockage of differentiation of GMPs or the depletion of GMPs in vivo or both have not been defined.
PU.1, a member of the Ets family of DNA-binding proteins, is encoded by the Sfpi1 gene and is an important transcriptional regulator that is required for the generation of early myeloid and lymphoid progenitors. 6 The PUER cells represent an experimentally manipulable cellular model system for analyzing molecular mechanisms that underlie macrophage differentiation in vitro. The PUER cells were originally derived from mouse PU.1 −/ − myeloid progenitors with expression of a conditionally active PU.1 protein fused to the ligand binding domain of the estrogen receptor (PUER). 7 Addition of 4-hydroxy-tamoxifen (4-OHT) leads to activation of PU.1 and differentiation of PUER cells. To test whether activation of Wnt/β-catenin signaling affects macrophage differentiation induced by PU.1 in PUER cells or not, we first expressed stabilized β-catenin mutant (β-catenin-S33Y) 8 in PUER cells by retroviral vector Migr1, which co-expresses EGFP ( Supplementary Figure 1a ). The expression of β-catenin-S33Y was confirmed by western blot (Supplementary Figure 1b ). The PUER cells were derived from the original PUER line that was established in Dr. Singh's laboratory. 7 The current cell line underwent monocyte/macrophage differentiation with a low concentration of 4-OHT. Upon 4-OHT addition, PUER protein is induced in PUER cells and the cells undergo differentiation into Mac-1 + /F4/80 + macrophages within 3-5 days (Supplementary Figure 2 ). Of interest, induction of PU.1 expression in PUER cells with expression of the stabilized β-catenin resulted in a significantly low number of Mac-1 + / F4/80 + cells (Figure 1a ). In the absence of 4-OHT, PUER cells with or without stabilized β-catenin displayed the morphology of myeloid progenitors with a large nucleus ( Figure 1b ). After treatment of 4-OHT for 5 days, the vector-expressing cells increased in size with an extensive cytoplasm morphologically resembling macrophages. In contrast, the PUER cells with stabilized β-catenin had the same morphology as the cells without 4-OHT treatment ( Figure 1b ). Taken together, these results suggest that stabilized β-catenin blocks PU.1-induced macrophage differentiation of PUER cells. Apc negatively regulates the Wnt/β-catenin pathway by controlling the turnover of β-catenin. 3 We next explored the consequences of knockdown of the Apc gene on macrophage differentiation in PUER cells. Inhibition of Apc by Apc shRNA 1 or 2 against Apc in PUER cells led to stabilization of β-catenin (Supplementary Figure 3 ). After induction of PU.1 for 3 days by 4-OHT treatment, PUER cells expressing Apc shRNA1 or 2 had a lower percentage of Mac-1 + /F4/80 + cells compared with the PUER cells expressing the control vector ( Figure 1c ), indicating that activation of the Wnt/β-catenin pathway by Apc inhibition also represses PU.1-induced macrophage differentiation of PUER cells. In consistence, we found that stabilized β-catenin also blocked granulocyte-macrophage colony stimulating factor (GM-CSF)driven macrophage differentiation of mouse primary bone marrow cells ( Figure 1d ).
Next, we determined whether activation of Wnt/β-catenin inhibits differentiation of human U973 cells exposed to PMA. We found that either expression of stabilized β-catenin ( Supplementary Figure 4a ) or knockdown Apc expression ( Supplementary Figures 5a and b ) significantly reduced the frequency of Mac-1 + and CD14 + cells of U937 cells after exposed to PMA ( Supplementary Figure 4b ; Figures 1e and f). Furthermore, stabilized β-catenin inhibits mRNA expression of CD14, Mac-1 and Csf1r genes induced by PMA in U937 cells, as determined by quantitative real time (qRT)-PCR ( Figure 1g ). As shown in Figure 1h , the morphological features associated with mature monocytes were observed in U937 cells expressing control vector but not β-cat-S33Y after PMA treatment for 48 h. These regulates suggest that activation of Wnt/β-catenin signaling inhibits PMA-induced monocyte/macrophage differentiation of U937 cells. Together, our studies demonstrate a negative role of β-catenin overexpression in monocyte/macrophage differentiation.
To understand the mechanism by which β-catenin inhibits PU.1-mediated monocyte differentiation, we performed microarray analysis of gene expression profiling of PUER cells with expression of stabilized β-catenin or control vector before and after 24 h induction of PU.1 expression. As shown in Supplementary Figure 6 , 505 genes were markedly upregulated whereas 390 genes were Accepted article preview online 23 May 2016; advance online publication, 17 June 2016 significantly downregulated by PU.1 gene expression (⩾2 or ⩽ 2-fold, FDRo0.01; Supplementary Table 1 ). Induction of PU.1 expression in PUER cells with expression of stabilized β-catenin for 24 h resulted in 505 genes upregulated by PU.1 with 219 genes significantly inhibited by stabilized β-catenin. However, of 390 genes downregulated by PU.1, 72 genes were upregulated by stabilized β-catenin (Supplementary Table 2 ; Figure 2a ), indicating that β-catenin significantly impairs PU.1-targeted gene transcription. Notably, 432% of PU.1-regulated genes were reversibly regulated by stabilized β-catenin, indicating that β-catenin overexpression antagonizes the function of PU.1 in myeloid progenitors.
Consistent with our microarray data, qRT-PCR analysis revealed that expression of a conditional version of PU.1-induced Egr2, Mmpl2, Emr1 and inhibited Gfi1 in PUER cells (Figure 2b) . Notably, stabilized β-catenin inhibited PU.1-induced Egr2, Mmpl2 and Emr1 and significantly increased Gfi1 expression. C/EBPα, which antagonizes PU.1-induced macrophage differentiation, 9 was also markedly upregulated by stabilized β-catenin in PUER cells after induction of PU.1. It is likely that β-catenin overexpression antagonizes PU.1-contolled gene transcription, partially through upregulating CEBPα and GFI1 expression.
Egr2 is a transcriptional master regulator that is regulated by PU.1 and cooperates with PU.1 in promoting monocyte-macrophage differentiation. It activates macrophage specific genes including Emr-1 and Mmpl2 and represses genes that promote neutrophil lineage differentiation, including Gfi1. 7 To determine whether stabilized β-catenin inhibited Egr2 expression in a human cell line during monocyte/macrophage differentiation, we expressed β-catenin-S33Y in U937 cells. EGR2 expression is determined by qRT-PCR before and after induction of monocyte/macrophage differentiation of U937 cells by PMA. Similarly, β-catenin-S33Y markedly suppressed PMA-induced EGR2 expression during U937 cell differentiation (Figure 2c ). Stabilized β-catenin significantly inhibited Egr2 expression in the absence of PU.1 gene expression, raising the possibility that β-catenin also directly regulates Egr2 expression. There are several predicted TCF4-binding sites identified on the promoter region of Erg2 ( Supplementary Figure 7) . Luciferase reporter showed that Egr2 promoter activity was repressed significantly with an increased amount of plasmids expressing stabilized β-catenin (Figure 2d ). Next, we performed chromatin immunoprecipitation (ChIP) assay followed by PCR. Our results revealed that both TCF4 and β-catenin binds directly to the predicted TCF4-binding sites in Egr2 promoter (Figure 2e ). To further determine whether downregulation of Egr2 has a critical role in mediating the inhibitory function of β-catenin in monocyte differentiation, we co-expressed Egr2 and β-catenin-S33Y in PUER and U937 cells. As shown in Figure 2f , forced expression of Egr2 reversed β-catenin-S33Y-induced inhibition of monocyte/macrophage differentiation of both PUER and U937 cells. In mouse primary BM cells, Egr2 expression was markedly increased at 12 h and 24 h after GM-CSF treatment. Notably, β-catenin-S33Y significantly blocked GM-CSF-induced Egr2 expression ( Figure 2g ). The luciferase reporter plasmid containing Egr2 promoter, control plasmids and plasmids expressing stabilized β-catenin were co-transfected into 293 T cells. The amount of β-catenin plasmids were increased gradually with gradually reduced amount of control plasmids to keep constant amount of plasmids added in each sample. Experiments were repeated for three times. (e) β-catenin and TCf4 directly binds the Egr2 promoter. β-catenin, TCF4 antibodies and IgG were used to perform the ChIP assay and PCR products were run on 2% gel. Specific DNA bands were amplified by primers of Site1 and Site2 from DNA immunoprecipitated by β-catenin or TCF4 antibodies but not control IgG. Experiments were repeated for two times. Moreover, forced expression of Egr2 reversed the inhibitory effect of stabilized β-catenin on monocyte/macrophage differentiation of primary BM cells (Figure 2h ). Together, stabilized β-catenin inhibits Egr2 expression in mouse primary BM cells, PUER and human U937 cells whereas forced expression of Egr2 released the blockage of monocyte-macrophage differentiation induced by stabilized β-catenin in these cells, suggesting an important role of Egr2 in mediating the negative effect of β-catenin overexpression in monocyte-macrophage differentiation.
β-Catenin overexpression is frequently detected in AML samples and it is associated with an adverse prognosis. 10, 11 By analysis of a published set of microarray data from BM cells from 69 AML patients and 18 control healthy individuals, 12 we found that a group of AML patients (15 out of 69) had a markedly increased β-catenin expression as compared to healthy individuals (P = 0.001) and the other AML patients (P = 5.65E − 10). Of interest, this group of AML patients with a high β-catenin expression displayed a reduced Egr2 expression in BM cells as compared with healthy individuals (P = 0.0156) and the other AML patients (P = 0.034; Figures 2i and j) . These data suggest that an increased expression of β-catenin likely inhibits Egr2 expression in BM cells in AML patients.
In summary, we have shown that β-catenin overexpression induced blockage of monocyte-macrophage differentiation by inhibiting PU.1-targeted gene transcription including Egr2 expression in myeloid progenitor cells. A recent study showed that minimal PU.1 reduction induces myeloid-biased preleukemic stem cells and promotes subsequent transformation to AML in the context of Msh2 deficiency. 13 Therefore, compromised PU.1-targeted gene transcription induced by β-catenin overexpression, at least partially, may mediate a pathogenic role of β-catenin in myeloid leukemia.
